“This FDA approval is a significant milestone for Guardant Health AMEA and it will certainly boost our efforts in offering Guardant360® as the first FDA approved tumor mutation profiling liquid biopsy test for Solid cancers in Asia, Middle East & Africa. We remain committed to making the Guardant360 test available to as many advanced cancer patients as possible so that they can undergo complete genotyping and have the best opportunity to receive the right treatment for their cancer,” said Mr Simranjit Singh, Chief Executive Officer of Guardant Health AMEA.

View full press release at this link: https://lnkd.in/gwAmpCD

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.